About Evaxion Biotech
Evaxion Biotech is a pioneering TechBio company leveraging its proprietary AI-Immunology™ platform for rapid vaccine target discovery, drug design, and development. The company's mission is to decode the human immune system to develop novel vaccines for cancer and infectious diseases. The AI-Immunology™ platform is clinically validated and uses artificial intelligence and machine learning to simulate the human immune system, generating predictive models that identify therapeutically relevant vaccine targets within 24 hours. In oncology, Evaxion creates truly personalized therapies tailored to individual patients, while in infectious diseases, the technology designs next-generation vaccines to address unmet medical needs. The platform consists of multiple proprietary AI building blocks including PIONEER™, EDEN™, ObsERV™, and RAVEN™ that can be intelligently combined to generate tailored AI prediction models for complex immune-related healthcare challenges. Evaxion maintains a broad pipeline of candidates with potential to revolutionize cancer prevention and treatment as well as infectious disease management. The company operates state-of-the-art facilities with multidisciplinary capabilities spanning AI immuno-informatics, animal facilities, laboratories, translational medicine, clinical development, and vaccine manufacturing. Since 2021, Evaxion has been publicly traded on the Nasdaq Capital Market under ticker EVAX. The company is headquartered in Hørsholm, Denmark, and pursues a multi-partner business model focused on vaccine target discovery, drug design, and development agreements with leading organizations.
Mission & Story
Mission
Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform
Clinical Focus
Medical conditions and clinical areas addressed by Evaxion Biotech.
Who It Serves
Milestones & Awards
Recent Milestones
Received Prix Galien UK Award for Best digital health solution (June 2026). Presented preclinical data for EVX-04 at EHA 2026 Congress (May-June 2026). IPO on U.S. Nasdaq in 2021.
Awards & Recognition
Prix Galien UK Award for Best digital health solution (2026)
Company Details
- Headquarters
- Hørsholm, Capital Region, Denmark
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.